dc.contributor.author | Ergen, A. | |
dc.contributor.author | Iplik, E.S. | |
dc.contributor.author | Ertugrul, B. | |
dc.contributor.author | Atas, M.N. | |
dc.contributor.author | Kasarci, G. | |
dc.contributor.author | Cakmakoglu, B. | |
dc.date.accessioned | 2021-12-21T08:40:48Z | |
dc.date.available | 2021-12-21T08:40:48Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 10191941 | |
dc.identifier.uri | https://doi.org/10.5472/marumj.815542 | |
dc.identifier.uri | http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/1205 | |
dc.description.abstract | Objective: Renal cancers are highly resistant to standard hormonal therapy, radiotherapy, and chemotherapy, and the survival rates are extremely low. Betulinic acid is a pentasilic triterpenoid saponin of lupine type obtained from various natural plants, | |
dc.description.sponsorship | In conclusion, we found with the results of Annexin-V, apoptosis-related nucleosomal enrichment factor levels measurement and Caspase 3/BCA activity that betulinic acid triggered apoptosis in both renal cancer cell lines, particularly through the caspase | |
dc.language.iso | English | |
dc.publisher | Marmara University | |
dc.rights | All Open Access, Bronze | |
dc.title | Examination of the apoptotic effects of betulinic acid on renal cancer cell lines | |
dc.type | Article | |
dc.relation.journal | Marmara Medical Journal | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 113 | |
dc.identifier.endpage | 118 | |
dc.identifier.volume | 33 | |
dc.identifier.doi | 10.5472/marumj.815542 | |
dc.relation.issue | 3 | |
dc.relation.volume | 33 | |